Share

August 2013; 3 (4) Five New Things

Neuro-oncology

Five new things

David Schiff, Benjamin Purow
First published August 19, 2013, DOI: https://doi.org/10.1212/CPJ.0b013e3182a1ba35
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
308

Share

Article Information

vol. 3 no. 4 326-333
DOI: 
https://doi.org/10.1212/CPJ.0b013e3182a1ba35
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • First Published August 19, 2013.
Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. David Schiff, MD and
    2. Benjamin Purow, MD
  1. David Schiff, MD and
    2. Scientific Advisory Boards:

    1. Genentech advisory board, November 2013 DSMBs for Celldex and Vascular Biogenics

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Travel related expenses without personal compensation, Merck Schering-Plough, March 2013.

    Editorial Boards:

    1. I serve on Neurology's editorial board.

    Patents:

    1. NONE

    Publishing Royalties:

    1. I receive royalties from UpToDate.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Tau Therapeutics

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Benjamin Purow, MD
    3. Scientific Advisory Boards:

    1. 1) Scientific Advisory Board, Parabon NanoLabs

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. 1) patent for sheath for chest tube

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1) Limited research funding for collaborative work with Parabon NanoLabs

    Research Support, Government Entities:

    1. NIH Research Project Grant (R01) Purow (PI) 9/01/08-7/31/13 Investigation of alpha-secretase inhibitors as Notch inhibitors and anti-glioma agents Specific Aims: To demonstrate that alpha-secretase inhibitors are a novel class of Notch inhibitors and have activity against established, primary, and stem cell glioma lines in vitro and in vivo NIH Research Project Grant (R01) Purow (PI) 2/01/09-12/31/13 Investigation of Notch-inhibiting microRNAs in glioma Specific Aims: To investigate two microRNAs we have found to inhibit the Notch pathway and assess their activity in vitro and in vivo against glioma cells, including glioma tumor stem cells

    Research Support, Academic Entities:

    1. UVA Cancer Center Translational Partnerships Initiative Purow (co-PI) 10/12-10/13 A Novel Nano-Theranostic for Diagnosing and Treating Glioblastoma Specific Aims: To investigate DNA-based theranostic nanoparticles for the diagnosis and treatment of brain tumors in xenografts

    Research Support, Foundations and Societies:

    1. Howard Hughes Medical Institute Physician-Scientist Early Career Award Purow (PI) 8/01/08-07/31/13 Investigation of microRNA-7 inhibition of key cancer pathways and as a potential therapy for glioma Specific Aims: To test the hypothesis that microRNA-7 is a physiologic inhibitor of key cancer pathways in human gliomas, to identify determinants of glioma cell sensitivity to microRNA-7, and to determine whether it can be delivered effectively in vivo as a glioma therapy

    Stock/Stock Options/Board of Directors Compensation:

    1. 1) Parabon NanoLabs

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. 1) Parabon NanoLabs

    Stock/Stock Options, Medical Equipment & Materials:

    1. 1) Parabon NanoLabs

    Legal Proceedings:

    1. NONE

  1. Departments of Neurology and Neuroscience, University of Virginia School of Medicine, Charlottesville.
  1. Correspondence to:
    ds4jd{at}virginia.edu
View Full Text

Article usage

Article usage: August 2013 to August 2023

AbstractFullPdfSource
Aug 20136254585Highwire
Sep 2013306818Highwire
Oct 2013187013Highwire
Nov 2013151113Highwire
Dec 20137213Highwire
Jan 20147637Highwire
Feb 20145821Highwire
Mar 20143812Highwire
Apr 20145211Highwire
May 20142661Highwire
Jun 20143000Highwire
Jul 20142102Highwire
Aug 20142002Highwire
Sep 20144002Highwire
Oct 20143926Highwire
Nov 20143013Highwire
Dec 20142300Highwire
Jan 20152702Highwire
Jan 20150156pmc
Feb 20152602Highwire
Feb 2015022pmc
Mar 20153612Highwire
Mar 2015073pmc
Apr 20151401Highwire
Apr 2015072pmc
May 20151904Highwire
May 2015087pmc
Jun 20151200Highwire
Jun 20150116pmc
Jul 20151800Highwire
Jul 2015090pmc
Aug 20152101Highwire
Aug 2015030pmc
Sep 20153104Highwire
Sep 20150155pmc
Oct 20151100Highwire
Oct 2015073pmc
Nov 20151901Highwire
Nov 2015078pmc
Dec 20152011Highwire
Dec 2015083pmc
Jan 20161200Highwire
Jan 20160126pmc
Feb 20161300Highwire
Feb 2016074pmc
Mar 20161302Highwire
Mar 2016020pmc
Apr 20163100Highwire
Apr 2016010pmc
May 20163700Highwire
May 2016021pmc
Jun 20162301Highwire
Jun 2016031pmc
Jul 20161401Highwire
Jul 2016024pmc
Aug 20162501Highwire
Aug 2016020pmc
Sep 20161602Highwire
Sep 2016011pmc
Oct 20161800Highwire
Nov 20163200Highwire
Nov 2016021pmc
Dec 20161300Highwire
Dec 2016021pmc
Jan 20171300Highwire
Jan 2017020pmc
Feb 20171502Highwire
Feb 2017011pmc
Mar 20171201Highwire
Mar 2017042pmc
Apr 20172002Highwire
Apr 2017132pmc
May 20171910Highwire
May 2017022pmc
Jun 20171600Highwire
Jun 2017011pmc
Jul 2017800Highwire
Jul 2017236pmc
Aug 20172302Highwire
Aug 2017344pmc
Sep 20171200Highwire
Sep 2017045pmc
Oct 20171300Highwire
Oct 2017044pmc
Nov 2017600Highwire
Nov 2017058pmc
Dec 2017710Highwire
Jan 2018600Highwire
Feb 20181411Highwire
Mar 20182401Highwire
Apr 20181300Highwire
Apr 2018011pmc
May 20182300Highwire
Jun 20181910Highwire
Jun 2018111pmc
Jul 20182400Highwire
Aug 20181600Highwire
Aug 2018022pmc
Sep 20181301Highwire
Oct 20181400Highwire
Nov 20181210Highwire
Dec 20181400Highwire
Jan 20191021Highwire
Feb 20191500Highwire
Mar 2019800Highwire
Apr 20191701Highwire
May 20191700Highwire
Jun 20191000Highwire
Jul 20191300Highwire
Aug 20191200Highwire
Sep 20191200Highwire
Oct 2019400Highwire
Nov 2019901Highwire
Dec 2019910Highwire
Jan 2020700Highwire
Feb 20201000Highwire
Mar 2020500Highwire
Apr 2020200Highwire
May 2020500Highwire
Jun 2020200Highwire
Jul 2020500Highwire
Aug 20201500Highwire
Sep 20201200Highwire
Oct 20203000Highwire
Nov 20201100Highwire
Dec 2020710Highwire
Jan 2021600Highwire
Feb 2021600Highwire
Mar 20211200Highwire
Apr 2021300Highwire
May 2021600Highwire
Jun 2021600Highwire
Jul 2021600Highwire
Aug 20211601Highwire
Sep 2021900Highwire
Oct 20211800Highwire
Nov 2021400Highwire
Dec 20211500Highwire
Jan 20221400Highwire
Feb 20221400Highwire
Mar 20221200Highwire
Apr 20221500Highwire
May 2022600Highwire
Jun 2022300Highwire
Jul 2022601Highwire
Aug 20221000Highwire
Sep 20221401Highwire
Oct 20221221Highwire
Nov 20223400Highwire
Dec 20221311Highwire
Jan 20231711Highwire
Feb 20232401Highwire
Mar 2023311Highwire
Apr 2023500Highwire
May 20231100Highwire
Jun 2023200Highwire
Jul 20231000Highwire
Aug 2023600Highwire

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles